Methodological approaches in application of synthetic lethality screening towards anticancer therapy

被引：22

作者：

Canaani, D. ^{[1
]}

机构：

[1] Tel Aviv Univ, Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel

来源：

BRITISH JOURNAL OF CANCER | 2009年 / 100卷 / 08期

关键词：

chemical synthetic lethality; chemical genetic interactions; genetic synthetic lethality; oncogenes; tumour suppressor genes; RNAi; RNA INTERFERENCE SCREEN; RENAL-CELL CARCINOMA; CULTURED HUMAN-CELLS; DNA-REPAIR; CANCER-CELLS; SACCHAROMYCES-CEREVISIAE; SMALL MOLECULES; TUMOR-CELLS; DRUG; GENE;

D O I：

10.1038/sj.bjc.6605000

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A promising direction in the development of selective less toxic cancer drugs is the usage of synthetic lethality concept. The availability of large-scale synthetic low-molecular-weight chemical libraries has allowed HTS for compounds synergistic lethal with defined human cancer aberrations in activated oncogenes or tumour suppressor genes. The search for synthetic lethal chemicals in human/mouse tumour cells is greatly aided by a prior knowledge of relevant signalling and DNA repair pathways, allowing for educated guesses on the preferred potential therapeutic targets. The recent generation of human/rodents genome-wide siRNAs, and shRNA-expressing libraries, should further advance this more focused approach to cancer drug discovery. British Journal of Cancer (2009) 100, 1213-1218. doi: 10.1038/sj.bjc.6605000 www.bjcancer.com Published online 24 March 2009 (C) 2009 Cancer Research UK

引用

页码：1213 / 1218

页数：6

共 43 条

[1] USE OF A SCREEN FOR SYNTHETIC LETHAL AND MULTICOPY SUPPRESSEE MUTANTS TO IDENTIFY 2 NEW GENES INVOLVED IN MORPHOGENESIS IN SACCHAROMYCES-CEREVISIAE [J].

BENDER, A ;

PRINGLE, JR .

MOLECULAR AND CELLULAR BIOLOGY, 1991, 11 (03) :1295-1305

[2] Validating cancer drug targets [J].

Benson, John D. ;

Chen, Ying-Nan P. ;

Cornell-Kennon, Susan A. ;

Dorsch, Marion ;

Kim, Sunkyu ;

Leszczyniecka, Magdalena ;

Sellers, William R. ;

Lengauer, Christoph .

NATURE, 2006, 441 (7092) :451-456

[3] Targeted rescue of a destabilized mutant of p53 by an in silico screened drug [J].

Boeckler, Frank M. ;

Joerger, Andreas C. ;

Jaggi, Gaurav ;

Rutherford, Trevor J. ;

Veprintsev, Dmitry B. ;

Fersht, Alan R. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (30) :10360-10365

[4] Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [J].

Bryant, HE ;

Schultz, N ;

Thomas, HD ;

Parker, KM ;

Flower, D ;

Lopez, E ;

Kyle, S ;

Meuth, M ;

Curtin, NJ ;

Helleday, T .

NATURE, 2005, 434 (7035) :913-917

[5] New approaches to molecular cancer therapeutics [J].

Collins, Ian ;

Workman, Paul .

NATURE CHEMICAL BIOLOGY, 2006, 2 (12) :689-700

[6] Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells [J].

Dolma, S ;

Lessnick, SL ;

Hahn, WC ;

Stockwell, BR .

CANCER CELL, 2003, 3 (03) :285-296

[7] Cell-based assays for identification of novel double-strand break-inducing agents [J].

Dunstan, HM ;

Ludlow, C ;

Goehle, S ;

Cronk, M ;

Szankasi, P ;

Evans, DRH ;

Simon, JR ;

Lamb, JR .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (02) :88-94

[8] shRNA-mediated RNA interference as a tool for genetic synthetic lethality screening in mouse embryo fibroblasts [J].

Einav, Y ;

Agami, R ;

Canaani, D .

FEBS LETTERS, 2005, 579 (01) :199-202

[9]

Einav Y, 2003, MOL CANCER THER, V2, P1121

[10] Mitochondriotoxic compounds for cancer therapy [J].

Fantin, V. R. ;

Leder, P. .

ONCOGENE, 2006, 25 (34) :4787-4797

← 1 2 3 4 5 →